% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Milde:283135,
      author       = {T. Milde$^*$ and J. Fangusaro and M. J. Fisher and C.
                      Hawkins and F. J. Rodriguez and U. Tabori and O. Witt$^*$
                      and Y. Zhu and D. H. Gutmann},
      title        = {{O}ptimizing preclinical pediatric low-grade glioma models
                      for meaningful clinical translation.},
      journal      = {Neuro-Oncology},
      volume       = {25},
      number       = {11},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2023-01922},
      pages        = {1920-1931},
      year         = {2023},
      note         = {#EA:B310# / 2023 Nov 2;25(11):1920-1931},
      abstract     = {Pediatric low-grade gliomas (pLGGs) are the most common
                      brain tumor in young children. While they are typically
                      associated with good overall survival, children with these
                      central nervous system tumors often experience chronic
                      tumor- and therapy-related morbidities. Moreover,
                      individuals with unresectable tumors frequently have
                      multiple recurrences and persistent neurological symptoms.
                      Deep molecular analyses of pLGGs reveal that they are caused
                      by genetic alterations that converge on a single mitogenic
                      pathway (MEK/ERK), but their growth is heavily influenced by
                      nonneoplastic cells (neurons, T cells, microglia) in their
                      local microenvironment. The interplay between neoplastic
                      cell MEK/ERK pathway activation and stromal cell support
                      necessitates the use of predictive preclinical models to
                      identify the most promising drug candidates for clinical
                      evaluation. As part of a series of white papers focused on
                      pLGGs, we discuss the current status of preclinical pLGG
                      modeling, with the goal of improving clinical translation
                      for children with these common brain tumors.},
      keywords     = {MAPK (Other) / genetically engineered mice (Other) /
                      pediatric low-grade glioma (Other) / preclinical models
                      (Other) / translation (Other)},
      cin          = {B310 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B310-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37738646},
      doi          = {10.1093/neuonc/noad125},
      url          = {https://inrepo02.dkfz.de/record/283135},
}